ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hou, M.-F.
Right arrow Articles by Huang, T.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hou, M.-F.
Right arrow Articles by Huang, T.-J.
Annals of Clinical & Laboratory Science 33:55-61 (2003)
© 2003 Association of Clinical Scientists

Diagnostic Value of Urine Deoxypyridinoline for Detecting Bone Metastases in Breast Cancer Patients

Ming-Feng Hou1, Shwu-Bin Lin2, Shyng-Shiou F. Yuan3, Li-Yu Tsai4, Shih-Meng Tsai5, Jan-Shih Hsieh1 and Tsung-Jen Huang1
1 Department of Surgery, Obstetrics and Gynecology, Kaohsiung Medical University;
2 School of Medical Technology, National Taiwan University;
3 Department of Laboratory Medicine, National Taiwan University and University Hospital;
4 Clinical Laboratory, Kaohsiung Medical University Hospital;
5 Department of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China

Address correspondence to Li-Yu Tsai, Ph.D., Clinical Laboratory, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung, Taiwan; tel 886 7 312 2805; fax 886 7 311 4679; e-mail mifeho{at}kmu.edu.tw.

Deoxypyridinoline (Dpd), a crosslink product of collagen molecules found in bone and excreted in urine during bone degradation, has been described as a marker of bone turnover in metastatic breast cancer. In this study, the urine deoxypyridinoline/creatinine (Dpd/Cre) ratio was determined by enzyme immunoassay in urine samples from 116 women with breast cancer. Bone metastases were confirmed by x-ray or CT scan, with follow-up >6 mo. The urine Dpd/Cre ratio was significantly higher in patients with bone metastasis, compared to those without bone metastasis (p <0.05). In patients with bone metastasis, ratios of urine Dpd/Cre were higher in those with multiple lesions, compared to those with a solitary lesion, and the values also reflected therapeutic response (p <0.05). Serial monitoring of urine Dpd/Cre revealed that an elevation was correlated with disease progression. Patients with stable bone disease under effective therapy had significant diminution of the urine Dpd/Cre ratios, compared to those with progression of bone disease (p <0.05). In conclusion, the urine Dpd/Cre ratio may be a useful marker for detecting bone metastases and evaluating their response to therapy.

Keywords: breast cancer, bone metastasis, deoxypyridinoline, tumor marker






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Association of Clinical Scientists.